Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
$16B Michigan Data Center Project Boosts U.S. AI Infrastructure Expansion 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
U.S. Raises Alarm Over Chinese AI Firms’ Alleged IP Theft Through Model Distillation 
MALVERN, Pa., March 29, 2017 -- PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing biopolymer-based drugs for the treatment of orphan diseases with an initial focus on cardiopulmonary disorders, today announced that Chief Executive Officer Jonathan P. Mow will present a company overview at Needham & Company’s 16th Annual Healthcare Conference on Wednesday, April 5, at 11:40 a.m. EDT at The Westin New York Grand Central in New York City.
For additional information on the conference, please visit:
http://www.needhamco.com/Default/InstitutionalSalesAndTrading/Conferences.aspx.
About PhaseBio
PhaseBio Pharmaceuticals is a clinical-stage biopharmaceutical company developing new and improved biotherapeutics for the treatment of orphan diseases, with a focus on cardiopulmonary disorders. The company’s proprietary technology platform uses recombinant elastin-like polypeptide (ELP) biopolymers to control the half-life, bioavailability and physical characteristics of molecules for ease of administration. The resulting compounds are engineered for a specific rate of absorption to enhance efficacy and reduce side effects, which can lead to less-frequent dosing and better patient compliance. PhaseBio's lead development candidate, PB1046, is a first-in-class weekly vasoactive intestinal peptide (VIP) receptor agonist for the treatment of pulmonary arterial hypertension (PAH); the treatment of cardiomyopathy associated with Duchenne muscular dystrophy (DMD), Becker muscular dystrophy (BMD) and X-linked dilated cardiomyopathy; and the treatment of cystic fibrosis. PhaseBio is privately owned, with headquarters and research laboratories in Malvern, PA. For more information, please visit www.phasebio.com.
Media Contact: Laura Bagby, 6 Degrees (312) 448-8098 [email protected]
